Cite
STMN1 as a novel prognostic biomarker in HCC correlating with immune infiltrates and methylation.
MLA
Zhang, En-di, et al. “STMN1 as a Novel Prognostic Biomarker in HCC Correlating with Immune Infiltrates and Methylation.” World Journal of Surgical Oncology, vol. 20, no. 1, Sept. 2022, pp. 1–17. EBSCOhost, https://doi.org/10.1186/s12957-022-02768-y.
APA
Zhang, E., Li, C., Fang, Y., Li, N., Xiao, Z., Chen, C., Wei, B., Wang, H., Xie, J., Miao, Y., Zeng, Z., & Huang, H. (2022). STMN1 as a novel prognostic biomarker in HCC correlating with immune infiltrates and methylation. World Journal of Surgical Oncology, 20(1), 1–17. https://doi.org/10.1186/s12957-022-02768-y
Chicago
Zhang, En-di, Chenxuan Li, Yuan Fang, Na Li, Zhongyun Xiao, Chuhong Chen, Benkai Wei, et al. 2022. “STMN1 as a Novel Prognostic Biomarker in HCC Correlating with Immune Infiltrates and Methylation.” World Journal of Surgical Oncology 20 (1): 1–17. doi:10.1186/s12957-022-02768-y.